Symmetric dimethylarginine (SDMA) is a biomarker utilized in veterinary medicine to assess kidney function, particularly in felines. It serves as an indicator of renal health. Elevated levels in a blood sample suggest compromised kidney function, often preceding changes detected by traditional creatinine or BUN (blood urea nitrogen) measurements. This allows for earlier identification of potential renal issues.
Early detection of kidney disease offers significant advantages in managing feline health. By identifying renal dysfunction at an earlier stage, interventions such as dietary adjustments, medication, and fluid therapy can be implemented sooner. These proactive steps can slow the progression of the disease, improve the animal’s quality of life, and potentially extend lifespan. This diagnostic advancement represents a marked improvement over relying solely on traditional renal markers, which often indicate substantial kidney damage has already occurred.